Type I Diabetes

The FDA has approved Provention Bio Inc's (NASDAQ: PRVB) proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab PK/PD substudy. Related Link: Provention Bio's Teplizumab Application Receives CRL For Type-1...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced Day 90 data for the first patient from the Phase 1/2 trial of VX-880 for type 1 diabetes (T1D).  VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy. The...

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes (T1D). Related: Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type...

The FDA has issued a Complete Response Letter (CRL) to Provention Bio Inc's (NASDAQ: PRVB) teplizumab marketing application seeking approval for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. The FDA stated that a single, low-dose pharmacokinetic/...

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes (T1D). Results were presented at the Federation of Clinical Immunology Societies 2021. Phase 1b AG019...

The search to find a cure for Type 1 Diabetes has continued with the acquisition of ULB (Universite Libre de Bruxelles) spin-off MaSTherCell by pre-clinical cell therapy and regenerative medicines company Orgenesis Inc (OTC: ORGS) on March 9. Scott Carmer, CEO of Orgenesis North America,...